$NNOX

Meltzer Erez purchased $10K of NNOX (indirect holdings)

Meltzer Erez (Chief Executive Officer) purchased 9,443 indirectly-held shares of Nano-X Imaging Ltd. (NNOX) at $1.03 on 2026-08-10.

Original reporting
SEC EDGAR · Meltzer Erez
Published Aug 11, 2026, 1:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 1:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NNOX
Bullish
medium confidence
Mentioned
$NNOX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NNOXBullishLow
01

Why it matters

The only new fact is the reported open-market purchase size, price, and post-transaction holdings; it does not include new business developments.

02

Market read

Traders may monitor for follow-on insider activity or corroborating fundamentals, but this filing alone is unlikely to drive a durable repricing.

03

What to watch

The article does not state whether the buy was opportunistic versus planned, and it provides no follow-on confirmation such as updated forecasts, trial results, or financing changes.

Relevance 3/10Novelty 3/10Timing: filed Aug. 11, covering a buy executed Aug. 10

Background

This is an SEC Form 4 insider transaction disclosure for Nano-X Imaging Ltd.

Company-level read

Ticker impact

$NNOXBullishMedium confidence
Context

CEO Meltzer Erez bought 9,443 shares of Nano-X Imaging at $1.0300/share via an indirect open-market purchase filed on Aug. 11.

Expected impact

Near-term impact likely limited; any reaction would be sentiment-driven and may fade without additional company-specific news.

Evidence & confidence

Insider buying can support sentiment, but the filing provides no new operational or financial information, and the transaction is not described as part of a 10b5-1 plan.

Market effects

Limited read-through to the imaging/healthtech sector because the disclosure is a single insider transaction without broader company guidance.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification-related, and the indirect nature of the holdings reduces interpretability.

Key entities

  • Nano-X Imaging Ltd.

    Subject of the Form 4 insider transaction disclosure (NNOX).

  • Meltzer Erez

    CEO and officer/director who purchased shares via an indirect open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NNOXMed

Nano X Imaging Ltd (NNOX) (Q2 2026) Earnings Call Highlights: Re

Nano X Imaging Ltd (NNOX) reported a 37% year-over-year revenue increase in Q2 2026, driven by growth in teleradiology services and new partnerships. The company also announced operational streamlining and cost reductions. However, NNOX recorded a $40.7 million impairment charge, a significant decrease in cash position, and a widened net loss of $55.5 million. Management expects revenue traction in the coming months and potential market expansion due to new reimbursement codes.

$NNOXHigh

Nano-X Imaging Ltd. (NNOX): Financial results for Q2 2026

Nano-X Imaging Ltd. (NNOX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Nanox Announces Second Quarter 2026 Financial Results and Provides Business Updates Management to host conference call and webcast on Wednesday, September 9, 2026 at 8:30 AM ET PETACH TIKVA, Israel — September 9, 2026 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or

$NNOXMed

NANO-X IMAGING LTD: Nanox and Vertec Scientific Enter Exclusive Sales Reseller Agreement for the Commercialization of Nanox.AI Bone Solution (HealthOST) in the United Kingdom

Nanox Imaging Ltd (NASDAQ: NNOX) said its subsidiary Nanox AI entered an exclusive UK sales reseller agreement with Vertec Scientific for commercialization of Nanox.AI bone solution (HealthOST). The initial three-year term requires Vertec to meet minimum annual license commitments. HealthOST is FDA-cleared and UKCA/CE-marked and was recommended by NICE in Nov 2025 for NHS use.